Analysts Set Envista Holdings Co. (NYSE:NVST) Price Target at $20.71

Envista Holdings Co. (NYSE:NVST) has been given an average rating of “Hold” by the fifteen ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and three have given a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $20.71.

NVST has been the topic of several analyst reports. Leerink Partners raised Envista from an “underperform” rating to a “market perform” rating and increased their target price for the stock from $16.00 to $23.00 in a research report on Thursday, October 31st. Bank of America cut their price objective on shares of Envista from $22.00 to $19.00 and set a “buy” rating on the stock in a research report on Thursday, August 8th. Robert W. Baird raised their price target on shares of Envista from $17.00 to $22.00 and gave the company a “neutral” rating in a research note on Thursday, October 31st. Evercore ISI boosted their price objective on Envista from $18.00 to $23.00 and gave the stock an “outperform” rating in a research report on Monday, September 23rd. Finally, Stifel Nicolaus raised their target price on Envista from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd.

Envista Price Performance

NVST opened at $20.57 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.77 and a current ratio of 2.08. Envista has a 1-year low of $15.15 and a 1-year high of $25.64. The company has a 50-day moving average of $19.20 and a 200-day moving average of $18.12. The company has a market capitalization of $3.54 billion, a P/E ratio of -2.65, a PEG ratio of 2.83 and a beta of 1.30.

Envista (NYSE:NVST) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.03. The firm had revenue of $601.00 million for the quarter, compared to analysts’ expectations of $590.34 million. Envista had a positive return on equity of 3.76% and a negative net margin of 53.42%. The firm’s revenue for the quarter was down 4.8% on a year-over-year basis. During the same period last year, the business posted $0.43 earnings per share. Equities analysts expect that Envista will post 0.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Envista

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jupiter Asset Management Ltd. bought a new stake in shares of Envista during the 2nd quarter worth $69,534,000. Pacer Advisors Inc. grew its position in shares of Envista by 11,202.8% in the second quarter. Pacer Advisors Inc. now owns 2,887,426 shares of the company’s stock valued at $48,018,000 after purchasing an additional 2,861,880 shares during the last quarter. Swedbank AB bought a new position in shares of Envista in the first quarter worth about $53,412,000. Nuance Investments LLC lifted its position in shares of Envista by 47.2% during the 2nd quarter. Nuance Investments LLC now owns 7,038,313 shares of the company’s stock worth $117,048,000 after purchasing an additional 2,256,993 shares during the last quarter. Finally, Iron Triangle Partners LP bought a new stake in Envista during the 3rd quarter valued at approximately $43,262,000.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.